تحميل...
Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus
OBJECTIVE: Hydroxychloroquine (HCQ) was not approved in Japan until 2015, and its therapeutic potential has not been explored in depth. We evaluated the additional therapeutic effect of HCQ in Japanese patients with systemic lupus erythematosus (SLE) on maintenance therapy. METHODS: Patients with SL...
محفوظ في:
| الحاوية / القاعدة: | Intern Med |
|---|---|
| المؤلفون الرئيسيون: | , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
The Japanese Society of Internal Medicine
2019
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6543229/ https://ncbi.nlm.nih.gov/pubmed/30626831 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.1999-18 |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|